Project Details
Description
Inflammation is the primary cause of cell death and organ dysfunction in many diseases. Research proposed in this application will open the possibility of using acute intravenous (IV) treatments of emulsion containing medium-chain and omega-3 (n-3) triglycerides enriched in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in targeting rapid n-3 fatty acid membrane enrichment as a new therapeutic approach to ameliorate adverse inflammatory responses. The planned experiments in cells and animal models will establish innovative methods that are adaptable for targeted, rapid delivery of oil-like therapeutic agents to specific cells or tissues, which will be significant to many fields, including immune responses to infection and inflammation-related tissue injury and organ dysfunction.
Status | Finished |
---|---|
Effective start/end date | 1/10/20 → 12/31/22 |
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases: US$347,787.00
- National Institute of Diabetes and Digestive and Kidney Diseases: US$405,000.00
- National Institute of Diabetes and Digestive and Kidney Diseases: US$307,147.00
ASJC Scopus Subject Areas
- Cell Biology
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.